Clinical Trial Update: Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients [NA]

View source ↗

Summary

A clinical trial evaluating the rivastigmine (Exelon) transdermal patch in amnestic mild cognitive impairment was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Exelon Transdermal Patch (rivastigmine)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Mild Cognitive Disorder, Mild Cognitive Impairment | NA | Status: TERMINATED | Results posted: 2017-02-28